NewAmsterdam Pharma (NAMS) Payables (2021 - 2026)

NewAmsterdam Pharma (NAMS) has 6 years of Payables data on file, last reported at $58.3 million in Q1 2026.

• For the quarter ending Q1 2026, Payables rose 96.96% year-over-year to $58.3 million; the trailing twelve-month figure through Mar 2026 stood at $58.3 million (up 96.96% YoY), and the FY2025 full-year result was $66.2 million, up 56.76% from the prior year.
• Payables declined to $58.3 million in Q1 2026, from $66.2 million in the prior quarter.
• In the past five years, Payables ranged from a high of $66.2 million in Q4 2025 to a low of $22.8 million in Q4 2022.
• A 5-year average of $37.6 million and a median of $30.4 million in 2023 frame the typical range for Payables.
• Across the five-year window, Payables soared 103.21% in 2022 and slipped 28.82% in 2025, its largest moves.
• Tracing NAMS's Payables over 5 years: stood at $22.8 million in 2022, then gained by 29.12% to $29.5 million in 2023, then soared by 43.26% to $42.3 million in 2024, then soared by 56.76% to $66.2 million in 2025, then slipped by 11.96% to $58.3 million in 2026.
• Business Quant data shows NAMS's Payables at $58.3 million in Q1 2026, $66.2 million in Q4 2025, and $48.0 million in Q3 2025.